IDH1 and acute myeloid leukemia: Recently, the US Food and Drug Administration approved the use of enasidenib (AG-221) and ivosidenib (AG-120) for the treatment of refractory or relapsed acute myeloid leukemia mutated in IDH2 or IDH1, respectively [46,47].